Zacks: Analysts Set $4.75 Price Target for Chiasma Inc. (CHMA)
Chiasma Inc. (NASDAQ:CHMA) has been assigned a consensus broker rating score of 3.00 (Hold) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold rating.
Analysts have set a 12 month consensus price objective of $4.75 for the company and are expecting that the company will post ($0.73) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Chiasma an industry rank of 105 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research lowered shares of Chiasma from a “hold” rating to a “sell” rating in a research note on Tuesday, October 11th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/zacks-analysts-set-4-75-price-target-for-chiasma-inc-chma.html
Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in Chiasma by 19.4% in the first quarter. Geode Capital Management LLC now owns 55,693 shares of the company’s stock worth $510,000 after buying an additional 9,038 shares during the period. Opaleye Management Inc. acquired a new stake in Chiasma during the first quarter worth $183,000. MPM Asset Management LLC raised its stake in Chiasma by 1.0% in the second quarter. MPM Asset Management LLC now owns 5,736,296 shares of the company’s stock worth $16,578,000 after buying an additional 54,752 shares during the period. Vanguard Group Inc. raised its stake in Chiasma by 25.7% in the second quarter. Vanguard Group Inc. now owns 426,477 shares of the company’s stock worth $1,233,000 after buying an additional 87,259 shares during the period. Finally, A.R.T. Advisors LLC acquired a new stake in Chiasma during the second quarter worth $441,000. 58.76% of the stock is owned by institutional investors.
Chiasma (NASDAQ:CHMA) traded down 1.296% during mid-day trading on Wednesday, reaching $2.665. 11,088 shares of the company’s stock were exchanged. The company’s 50-day moving average is $2.77 and its 200 day moving average is $3.47. Chiasma has a one year low of $2.40 and a one year high of $24.78. The firm’s market capitalization is $64.91 million.
Chiasma (NASDAQ:CHMA) last issued its earnings results on Wednesday, August 10th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.47. Equities analysts predict that Chiasma will post ($3.14) earnings per share for the current fiscal year.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.